Current Size: 100%

New paper out on BRCA-mutations in brain metastasis

Ovarian cancer represents the most common gynaecological malignancy and has the highest mortality of all female reproductive cancers. It has a rare predilection to develop brain metastases. Lukas Kenner has now contributed to a report on Next-Generation Sequencing (NGS)-based genomic profiling of brain metastases of primary ovarian cancer. The team from Vienna identified a high number of BRCA-mutations with a NGS study of samples from ovarian carcinoma, besides TP53, ATM and CHEK2 mutations. These findings strongly suggest the implication of BRCA and DNA repair malfunction in ovarian cancer metastasizing to the brain. Based on these findings, pharmacological PARP inhibition could be one potential targeted therapeutic for brain metastatic ovarian cancer patients.
Please check the original publication in the Journal of Neuro-Oncology